Daily Respiratory Research Analysis
Three impactful papers advance respiratory medicine across therapy, stewardship, and diagnostics. A randomized, double-blind study shows the dual NOP–MOP agonist cebranopadol produces less respiratory depression than oxycodone at equianalgesia. A large multicenter analysis finds no outcome benefit from 5–7 days of antibiotics in hospitalized viral CAP, supporting stewardship. A multicenter CT radiomics model accurately diagnoses and risk-stratifies pulmonary hypertension and outperforms ESC 4-st
Summary
Three impactful papers advance respiratory medicine across therapy, stewardship, and diagnostics. A randomized, double-blind study shows the dual NOP–MOP agonist cebranopadol produces less respiratory depression than oxycodone at equianalgesia. A large multicenter analysis finds no outcome benefit from 5–7 days of antibiotics in hospitalized viral CAP, supporting stewardship. A multicenter CT radiomics model accurately diagnoses and risk-stratifies pulmonary hypertension and outperforms ESC 4-strata prognostic assessment.
Research Themes
- Opioid analgesia with reduced respiratory depression
- Antibiotic stewardship in viral community-acquired pneumonia
- AI radiomics for pulmonary hypertension diagnosis and prognosis
Selected Articles
1. Respiratory and antinociceptive effects of NOP-MOP agonist cebranopadol versus full opioid receptor agonist oxycodone: a comparison in healthy volunteers.
In a randomized, double-blind, partial-crossover study, cebranopadol produced significantly less respiratory depression than oxycodone at comparable analgesic levels and showed greater analgesic potency. Oxygen desaturation events were markedly fewer with cebranopadol 1000 µg than with oxycodone 60 mg.
Impact: Demonstrates a potential opioid analgesic with a substantially improved respiratory safety profile, addressing a central harm of opioid therapy. Mechanistic PK/PD data strengthen translational relevance.
Clinical Implications: Cebranopadol may offer safer analgesia with reduced risk of opioid-induced respiratory depression, meriting evaluation in patient populations with pain (postoperative, cancer) and respiratory vulnerability.
Key Findings
- Cebranopadol 600 µg produced less respiratory depression than oxycodone 30 mg (p=0.022) at comparable analgesia.
- Oxygen desaturation to ~80% occurred in 65% with oxycodone 60 mg vs 25% with cebranopadol 1000 µg.
- PK/PD analysis showed much lower respiratory C50 for cebranopadol (0.20±0.54) vs oxycodone (36±6 ng/mL), with cebranopadol more potent for analgesia.
Methodological Strengths
- Randomized, double-blind, placebo-controlled, partial-crossover design
- Integrated PK/PD modeling of both respiratory and analgesic endpoints
Limitations
- Healthy volunteer study limits generalizability to clinical pain populations
- Modest sample with complex dosing scheme; not powered for rare adverse events
Future Directions: Evaluate cebranopadol in postoperative and chronic pain patients, including those with respiratory comorbidities; head-to-head comparisons across opioid classes; real-world safety monitoring for respiratory events.
BACKGROUND: The novel analgesic cebranopadol targets the nociceptin (NOP) and mu-opioid (MOP) receptor, acting as a novel full dual NOP-MOP-receptor agonist, with possible differences in respiratory effects compared to selective MOP-opioids like oxycodone. METHODS: In this randomized, double-blind, placebo-controlled study, 30 healthy volunteers received oral placebo (n=20), cebranopadol (600 µg, n=20; 800 µg, n=20; or 1000 µg, n=20) or oxycodone (30 mg, n=20; or 60 mg, n=20) on 4 occasions in a partial-crossover design. On each occasion ventilation at an extrapolated isohypercapnic level of 55 mmHg (V̇E55) derived from hypercapnic ventilatory responses and electrical pain tolerance tests were obtained at regular intervals before and for 24 h after drug intake. Mixed model analyses on respiratory endpoints was performed (primary endpoint) as well as an exploratory population pharmacokinetic/pharmacodynamic analyses on respiratory and analgesic endpoints. RESULTS: Oxygen desaturations (to ∼80%) were observed in 65% of subjects after oxycodone 60 mg versus cebranopadol 1000 µg in 25% of subjects (all occurring in between respiratory or pain testing). A significant main effect and a significant separation of all cebranopadol and oxycodone doses versus placebo (all p<0.0001) was observed with cebranopadol 600 μg producing less respiratory depression than oxycodone 30 mg (p=0.022). Pharmacokinetic/pharmacodynamic analyses showed that respiratory C50 values (drug concentration causing 50% effect) was 0.20±0.54 for cebranopadol versus 36±6 ng/mL for oxycodone. Cebranopadol was more potent than oxycodone in producing analgesia. CONCLUSIONS: The primary endpoint showed separation between the respiratory effects of cebranopadol and oxycodone, with 25% less respiratory depression at equianalgesia, as observed in the pharmacokinetic/pharmacodynamic analysis.
2. Chest Computed Tomography-Based Radiomics for the Diagnosis and Prognosis of Pulmonary Hypertension.
A multicenter chest CT radiomics model integrating pulmonary vascular features with clinical data achieved AUC ~0.98 for PH diagnosis and outperformed the ESC 4-strata risk tool for 2‑year prognosis (AUC 0.866 vs 0.709). External validation supported generalizability despite smaller cohorts.
Impact: Demonstrates noninvasive, high-accuracy PH diagnosis and risk stratification directly from routine chest CT, potentially enabling earlier detection and more precise therapy without invasive hemodynamics.
Clinical Implications: Radiomics could complement echocardiography and right heart catheterization by flagging high-risk PH patients from standard CT scans, guiding earlier referral and more tailored therapy.
Key Findings
- Diagnostic radiomic-clinical model achieved AUC 0.984 (derivation) and 0.980 (external validation) for PH detection.
- Prognostic model’s 2-year AUC (0.866) exceeded ESC 4-strata risk assessment (0.709).
- Exploratory pulmonary arterial hypertension subtyping reached internal AUC 0.898 and external AUC 0.877.
Methodological Strengths
- Multicenter cohorts with external validation
- Prospective follow-up for prognostic assessment and comparison against guideline risk tool
Limitations
- External validation sample sizes were modest, potentially inflating uncertainty bounds
- Radiomics reproducibility depends on CT acquisition/segmentation standardization
Future Directions: Harmonize CT protocols and validate across broader scanners and populations; integrate with hemodynamics for hybrid risk scores; assess impact on clinical decision-making and outcomes.
BACKGROUND: Imaging technique has emerged as an innovative tool for diagnosing and monitoring patients with pulmonary hypertension (PH). Current studies in radiomics primarily focus on hemodynamics and cardiac function, whereas the assessment of pulmonary vessels is often neglected. This study aims to investigate the diagnostic and prognostic value of computed tomography pulmonary vascular radiomics in PH. METHODS: This multicenter study enrolled 193 patients with PH and 193 controls (102 symptomatic non-PH cases and 91 healthy volunteers) for diagnostic analysis, with external validation in 38 patients with PH and 38 controls. For prognostic analysis, 166 patients with PH were prospectively followed (median follow-up: 16 months; 96 clinical deterioration events), with external validation in 32 patients with PH (median follow-up: 7 months; 11 events). Pulmonary vascular radiomics features extracted from chest computed tomography were used to develop predictive models for PH diagnosis and prognosis. RESULTS: The diagnostic model integrating 7 radiomic and 3 clinical features achieved an area under the curve of 0.984 (95% CI, 0.959-0.995) in the derivation cohort and 0.980 (0.901-1.000) in external validation. For exploratory pulmonary arterial hypertension subtyping, the model incorporating 8 radiomic and 2 clinical features yielded an area under the curve of 0.898 (0.825-0.972) internally and 0.877 (0.352-1.000) externally. The prognostic radiomic-clinical model outperformed the European Society of Cardiology 4-strata risk assessment, with a 2-year area under the curve of 0.866 (0.8-0.942) versus 0.709 (0.648-0.789). CONCLUSIONS: The radiomics-based models have strong diagnostic and prognostic capabilities for PH and can also successfully differentiate pulmonary arterial hypertension. This suggests the potential of radiomics to discern PH with different clinical risks, which may facilitate personalized drug therapy.
3. Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays.
Across 5 hospitals and 6,779 viral-positive possible CAP admissions, propensity-weighted comparisons showed no benefit of 5–7 days of antibiotics versus 0–2 days for LOS, delayed ICU transfer, in-hospital mortality, or 30-day hospital-free days. Findings persisted in non-SARS-CoV-2 and influenza-only subsets.
Impact: Challenges a conditional recommendation to routinely give antibiotics in viral-positive CAP by demonstrating no measurable outcome benefit, with major implications for antimicrobial stewardship.
Clinical Implications: In hospitalized CAP patients with a confirmed respiratory virus, clinicians should reconsider routine multi-day antibiotics in the absence of bacterial evidence, supporting shorter courses or early discontinuation strategies.
Key Findings
- No significant differences in LOS (11.7 vs 11.1 days), late ICU admission (28.3% vs 28.2%), in-hospital mortality (9.5% vs 9.8%), or 30-day hospital-free days (16.9 vs 17.0) between 0–2 vs 5–7 days antibiotics.
- Results were consistent when limited to non–SARS‑CoV‑2 viruses, to influenza alone, to 0 vs 5–7 days of antibiotics, and when restricted to pneumonia present-on-admission ICD‑10 codes.
- Antibacterial prescribing for viral-positive CAP was highly variable across hospitals, indicating opportunities for stewardship.
Methodological Strengths
- Large multicenter cohort with detailed clinical data and propensity weighting
- Robust sensitivity analyses across viral subgroups and coding restrictions
Limitations
- Retrospective observational design susceptible to residual confounding
- Potential misclassification of bacterial coinfection and variability in viral testing
Future Directions: Prospective trials to test antibiotic de-escalation protocols in viral CAP, incorporation of rapid diagnostics (e.g., procalcitonin, mNGS), and stewardship pathways tailored to local epidemiology.
BACKGROUND: Newly released community-acquired pneumonia (CAP) guidelines include a conditional recommendation to treat all hospitalized patients with positive respiratory virus assays with antibacterials. We assessed the frequency, duration, and outcomes of antibacterial prescribing in this population. METHODS: We retrospectively identified all hospitalized patients with possible CAP and a positive respiratory virus test at five hospitals, June 2015-December 2024. We used detailed clinical data to propensity-weight patients treated with 0-2 vs 5-7 days of antibacterials and compared outcomes overall and for different viruses. RESULTS: Among 6779 patients with possible CAP and a respiratory virus, 3269 were treated with 0-2 days and 1560 with 5-7 days of antibacterials. After propensity-weighting 2614 patients (1720 treated 0-2 days, 894 treated 5-7 days), there were no significant differences in hospital length of stay (11.7 days vs 11.1 days; OR 1.05, 95% CI 0.97-1.15), ICU admission after 48 hours (28.3% vs 28.2%; OR 1.01, 95% CI 0.86-1.18), in-hospital mortality (9.5% vs 9.8%; OR 0.97, 95% CI 0.74-1.27), or 30-day hospital-free days (16.9 days vs 17.0 days; OR 0.99, 95% CI 0.95-1.03). Results were consistent when restricted to non-SARS-CoV-2 viruses and to influenza alone, when comparing 0 vs 5-7 days of antibacterials, and when restricting to patients with ICD-10 codes for pneumonia present on admission. CONCLUSIONS: Antibacterial use for patients with possible CAP and respiratory viruses is highly variable but outcomes are similar with 0-2 vs 5-7 days of antibacterials. This suggests antibiotics are not beneficial in most CAP patients who test positive for respiratory viruses.